Oxford Initiates European Enrollment for FORTIFY Trial Testing Orticumab in Post-Heart Attack Inflammation
核心洞察
Oxford University (搜索) has recruited the first European participant for the FORTIFY clinical trial, testing orticumab, a monoclonal antibody targeting coronary inflammation in post-heart attack patients.
The international study, sponsored by Abcentra, will enroll approximately 240 participants across the United States and Europe who have elevated coronary inflammation measured by the Oxford-developed FAI score.
Orticumab works by binding to oxidized low-density lipoprotein to reduce arterial inflammation, representing a novel therapeutic approach for cardiovascular risk reduction.
Oxford University (搜索) has achieved a significant milestone in cardiovascular research by recruiting the first European participant for the FORTIFY clinical trial, an international study testing orticumab as a potential treatment for coronary inflammation in patients who have experienced heart attacks. The recruitment was conducted by the team at the Acute Multidisciplinary Imaging and Interventional Centre (AMIIC), a state-of-the-art facility in the Radcliffe Department of Medicine that integrates interventional procedures, non-invasive imaging, and artificial intelligence capabilities.
Novel Monoclonal Antibody Targets Post-Cardiac Event Inflammation
The FORTIFY study, sponsored by US biopharmaceutical company Abcentra, is evaluating orticumab, a human monoclonal antibody designed as an anti-inflammatory treatment specifically for heart inflammation. The trial plans to enroll approximately 240 participants across the United States and Europe, all of whom share the common characteristic of having experienced a previous heart attack and currently exhibiting high levels of coronary inflammation.
Orticumab represents a targeted therapeutic approach, functioning as an antibody that reduces inflammation in the heart's arteries by binding to oxidized low-density lipoprotein, a harmful form of cholesterol known to promote inflammatory processes. This mechanism of action addresses a critical pathway in post-cardiac event complications, where persistent inflammation can contribute to increased cardiovascular risk.
Oxford-Developed Biomarker Guides Patient Selection
The trial's patient selection strategy relies on the fat attenuation index (FAI) score, a diagnostic method developed at the University of Oxford and commercialized through the Oxford spin-out company Caristo Diagnostics (搜索). This technology measures structural changes in the peri-vascular adipose tissue surrounding coronary arteries using routine coronary computed tomography angiography, commonly known as a heart CT scan.
The FAI score has emerged as an important biomarker indicating greater inflammation and increased risk of heart attacks, with clinical implementation already established within the NHS and other healthcare systems globally. A high FAI score serves as the inclusion criterion for the FORTIFY trial, ensuring that participants represent the population most likely to benefit from anti-inflammatory intervention.
Clinical Significance and Research Leadership
British Heart Foundation Professor Charis Antoniades, who developed the FAI score and serves as the principal investigator for the FORTIFY trial in the UK, emphasized the study's potential impact on cardiovascular care. "We are becoming better at identifying those people who are at greatest risk of a heart attack, and this trial is an opportunity to see if orticumab, this new experimental drug, is effective at reducing inflammation in the heart after a cardiac event," Antoniades stated.
The professor highlighted the recruitment of the first European participant as "an important milestone in this trial," underscoring the significance of expanding the study beyond its initial US sites. This international expansion allows for broader patient diversity and enhanced statistical power to evaluate orticumab's therapeutic potential.
Advanced Imaging Technology Integration
The AMIIC facility's role in the trial demonstrates the integration of cutting-edge imaging technologies with clinical research. The center's combination of interventional capabilities, non-invasive imaging, and artificial intelligence represents a comprehensive approach to cardiovascular research and patient care. This technological infrastructure supports both the precise patient selection required for the FORTIFY trial and the sophisticated monitoring needed to assess treatment outcomes.
The trial's reliance on routine CT angiography for patient identification and monitoring represents a practical advantage, as this imaging modality is widely available in clinical practice. This accessibility could facilitate broader implementation of FAI score-based risk assessment and potential future therapeutic monitoring if orticumab proves successful.